Brigida Anna Maiorano

Vita-Salute San Raffaele University — Italy

Medicine · Health Sciences

21h-index1.0kcitations130works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(31), Bladder and Urothelial Cancer Treatments(25), Ovarian cancer diagnosis and treatment(17), PARP inhibition in cancer therapy(17), Renal cell carcinoma treatment(15)

Publications128 total

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25
Cancer Immunology Immunotherapy·2026Open Access
Tamoxifen interruption to pursue pregnancy in pre-menopausal hormone receptor–positive breast cancer patients: a systematic review of oncological safety and reproductive outcomes
International Journal of Gynecological Cancer·2026
First-line treatments for BCG-naïve non-muscle invasive bladder cancer: a systematic review and meta-analysis
World Journal of Urology·2026Open Access
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non–muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials
European Urology·2025· 2 cited
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study
The Oncologist·2025Open Access
Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study
ESMO Open·2025Open Access
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)
The Oncologist·2025· 1 citedOpen Access
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis
The Oncologist·2025Open Access
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study
2025Open Access
Impact of timing between neoadjuvant therapy and radical cystectomy on survival in muscle-invasive bladder cancer
World Journal of Urology·2025
450 Outcomes of immune-checkpoint inhibitors rechallenge in metastatic clear cell renal cell carcinoma: results from a global real-world evidence study
Regular and Young Investigator Award Abstracts·2025Open Access
Impact of neoadjuvant chemotherapy dose intensity on pathological response and survival in muscle-invasive urothelial carcinoma
European Urology Open Science·2025Open Access
Stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (OMOC): a systematic review and meta-analysis of clinical outcomes and toxicity profiles
Frontiers in Pharmacology·2025Open Access
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)
European Urology Open Science·2025· 1 citedOpen Access
Addition of androgen-receptor pathway inhibitors to standard of care in metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
Urologic Oncology Seminars and Original Investigations·2025
2639P Outcomes of immune-checkpoint inhibitors (ICIs) rechallenge in metastatic clear cell renal cell carcinoma (mccRCC): Results from a global real-world evidence study
Annals of Oncology·2025
LBA110 A blinded, exploratory phase II trial of nivolumab and the GDF-15 neutralizing antibody visugromab or placebo as neoadjuvant treatment of patients with muscle-invasive bladder cancer (MIBC): Primary results of the GDFather-NEO trial
Annals of Oncology·2025· 1 citedOpen Access
2680eP Metastatic fumarate hydratase-deficient renal cell carcinoma (FHRCC): outcome on first-line immune checkpoint inhibitor (ICI) combination: a multicenter retrospective study (FUMAHRE study)
Annals of Oncology·2025
2440P ARPI-based triple and double therapy in metastatic hormone-sensitive prostate cancer: a real-world analysis
Annals of Oncology·2025Open Access
2430P Prognostic impact of variants of uncertain significance (VUS) in homologous recombination repair (HRR) genes in prostate cancer (PC) outcome: A real-word Multicenter Study
Annals of Oncology·2025
page 1 of 7Next →

Frequent Co-authors

Evaristo Maiello(26), Giovanni Schinzari(17), Giampaolo Tortora(16), Davide Ciardiello(14), Ernesto Rossi(13), Mauro Francesco Pio Maiorano(11), Emilio Bria(7), Ketty Peris(7), Giandomenico Roviello(7), Massimo Di Maïo(7), Domenica Lorusso(6), Gennaro Cormio(6), Ugo De Giorgi(6), Roberto Iacovelli(6), Jacopo Romagnoli(6), Alessandro Di Stefani(5), Giuseppe Procopio(5), Vincenza Conteduca(5), Chiara Mercinelli(5), Andrea Necchi(5)